USFDAAug 12, 2026, 04:10 PM
Spero Therapeutics' Utebzi FDA Approved; Secures $105M Royalty Financing
AI Summary
Spero Therapeutics announced the FDA approval of Utebzi (tebipenem pivoxil) in June 2026 for complicated urinary tract infections. Following this, the company secured a $105.0 million royalty financing transaction with HCRx, tied to future GSK proceeds from Utebzi. The company has shifted its focus to advancing SP001, a monoclonal antibody for immune-mediated diseases, and entered into an exclusive licensing agreement with Innovent for its development and commercialization outside the Innovent Territory. Spero Therapeutics reported a net loss of $9.6 million for Q2 2026 and $16.8 million for the six months ended June 30, 2026, and continues to operate with an accumulated deficit of $467.8 million.
Key Highlights
- FDA approved Utebzi (tebipenem pivoxil) in June 2026.
- Secured $105.0 million royalty financing from HCRx.
- Entered exclusive licensing agreement with Innovent for SP001.
- Net loss of $9.55 million for Q2 2026.
- Net loss of $16.76 million for H1 2026.
- Cash and cash equivalents increased to $50.77 million as of June 30, 2026.
- Accumulated deficit reached $467.82 million as of June 30, 2026.
- Research and development expenses decreased to $3.43 million in Q2 2026.
Price Impact
More from SPRO